Private Melinta raises $70m for Phase III antibiotic delafloxacin
This article was originally published in Scrip
Executive Summary
Melinta Therapeutics has $70m in new private capital for Phase III development of delafloxacin and to pursue US FDA approval for the antibiotic's first indication.